Status:

COMPLETED

Precise Percutaneous Coronary Intervention Plan (P3) Study

Lead Sponsor:

Onze Lieve Vrouw Hospital

Conditions:

Stable Coronary Artery Disease

Eligibility:

All Genders

18+ years

Brief Summary

The PRECISE PERCUTANEOUS CORONARY INTERVENTION (PCI) PLAN STUDY is an investigator-initiated, international and multicenter study of patients with an indication for PCI aiming at assessing the agreeme...

Detailed Description

Multicenter study, including 120 patients at 5 centers in Europe and Asia. After identifying the presence of significant coronary stenosis by means of coronary angiography and invasive fractional flow...

Eligibility Criteria

Inclusion

  • Coronary artery disease in a major epicardial vessel with an invasive fractional flow reserve (FFR) ≤0.80
  • An indication to Percutaneous coronary intervention

Exclusion

  • \- Angiographic exclusion criteria
  • Severely calcified lesion/vessel
  • Bifurcation lesions.
  • Ostial lesions.
  • Left main disease.
  • Severe vessel tortuosity.
  • Clinical exclusion criteria
  • Chronic obstructive pulmonary disease
  • Contraindication to adenosine
  • NYHA class III or IV, or last known left ventricular ejection fraction \<30%
  • Uncontrolled or recurrent ventricular tachycardia
  • Atrial fibrillation, flutter or arrhythmia
  • History of recent stroke (≤90 days)
  • History of acute coronary syndrome (≤90 days)
  • Prior myocardial infarction
  • History of ischemic stroke (\>90 days) with modified RANKIN score ≥ 2
  • History of any hemorrhagic stroke
  • Previous revascularization (PCI or Coronary artery bypass grafting)
  • Active liver disease or hepatic dysfunction, defined as AST or ALT \> 3 times the ULN
  • Severe renal dysfunction, defined as an eGFR \<30 mL/min/1.73 m2
  • Body mass index\>35 kg/m2
  • Nitrate intolerance
  • Contra-indication to heart rate lowering drugs
  • Imaging-related
  • Insufficient coronary CT Angiography image quality.

Key Trial Info

Start Date :

February 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 18 2021

Estimated Enrollment :

127 Patients enrolled

Trial Details

Trial ID

NCT03782688

Start Date

February 1 2019

End Date

December 18 2021

Last Update

March 23 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

OLV-Aalst

Aalst, Oost-Vlaanderen, Belgium, 9300